University of Notre Dame Du Lac

Miltenyi Biotec, Gmbh

Klinikum Der Universitat Munchen

Leibniz Institute For Natural Product Research And Infection Biology—hans Knoll Institute

Leibniz-institut Fuer Naturstoff-forschung Und Infektionsbiologie E.v. Hans-knoell-institute (hki)

Leibniz-institut Für Naturstoff-forschung Und Infektionsbiologie E.v. -hans-knöll-institut- (hki)

Axel Brakhage

Marvin J Miller

Alexander Scheffold

Christian Hertweck

Hans-Martin Dahse

Florian Kloss

Ute Möllmann

Kirstin Scherlach

Sebastian Schieferdecker

Julia Dreisbach

Kamil Philip Wojtas

Petra Bacher

Olaf Kniemeyer

Janka Teutschbein

Hans-Wilhelm Nuetzmann

The present invention relates to the general field of treatment of infectious diseases of mammals (humans and animals) caused by bacteria, in particular to the treatment of diseases like tuberculosis (TB), Buruli ulcer and leprosy caused by mycobacteria. The invention aims at the generation of a new series of benzothiazinone compounds having the potential to overcome the above mentioned problems. In a preferred embodiment the invention is concerned with compounds of the general formula (I) whereinRrepresents NO,Rrepresents CF,at least one of the substituents Rand Ris OH, SR, NHR, CN, N, a saturated or unsaturated, optionally halogenated, linear or branched aliphatic radical having 1-4 carbon atoms, linear or branched C-Calkoxy, C-Cacyl, and the other of Rand Rmay in addition be hydrogen,Rrepresents a 2-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl or a 4-(cyclo-hexylmethyl)piperazin-1-yl group andRand Rindependently of each other are hydrogen or a C-Calkyl group and/or a pharmaceutically acceptable salt thereof.

Antimicrobial compounds, their use for the treatment of mammalian infections and a new metabolic mechanism

The present invention provides the in-vitro use of at least one in-vivo-target antigen offor selective activation, detection and/or analysis ofspecific CD4T cells in a sample comprising cells, wherein said at least one in-vivo-target antigen reveals an immune reactivity characterized by i) the in vivo existence of antigen-specific T cells comprising more than 60% memory T cells and ii) said antigen-specific T cells further comprise T cells able to produce IFN-gamma upon stimulation at a frequency between 15% and 80% and/or IL17 upon stimulation at a frequency between 5% and 30%. Said at least one in-vivo-target antigen may be selected from the group consisting of antigens Scw4, Pst1, Shm2, GliT and TpiA or fragments thereof. Also provided are a method, a composition, and a kit thereof.

[object Object]

This invention relates to the field of biologically active compounds and specifically to phaeofungins, of the general formula (I) or a pharmacologically acceptable salt, solvate, hydrate or a pharmacologically acceptable formulation thereof, pharmaceutical compositions comprising these compounds, methods for the production of the phaeofungins and their use as fungicide, antibiotic as well as antitumor agent. 

Benzopyranobenzothiazinones and their use as fungicides, antibiotics and antitumor agents

Growing community of inventors

Weimar, Germany

Axel Brakhage